![](/images/graphics-bg.png)
Maternal LopinavirRitonavir Is Associated with Fewer Adverse Events in Infants than Nelfinavir or Atazanavir
المؤلفون المشاركون
Davies, Jill
McFarland, Elizabeth J.
Smith, Christiana
Forster, Jeri E.
Pappas, Jennifer
Kinzie, Kay
Barr, Emily
Paul, Suzanne
Levin, Myron J.
Weinberg, Adriana
المصدر
Infectious Diseases in Obstetrics and Gynecology
العدد
المجلد 2016، العدد 2016 (31 ديسمبر/كانون الأول 2016)، ص ص. 1-9، 9ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2016-04-04
دولة النشر
مصر
عدد الصفحات
9
التخصصات الرئيسية
الملخص EN
Combination antiretroviral therapy (cART) is successfully used for prevention of perinatal HIV transmission.
To investigate safety, we compared adverse events (AE) among infants exposed to different maternal cART regimens.
We reviewed 158 HIV-uninfected infants born between 1997 and 2009, using logistic regression to model grade ≥1 AE and grade ≥3 AE as a function of maternal cART and confounding variables (preterm, C-section, illicit drug use, race, ethnicity, infant antiretrovirals, and maternal viremia).
Frequently used cART regimens included zidovudine (63%), lamivudine (80%), ritonavir-boosted lopinavir (37%), nelfinavir (26%), and atazanavir (10%).
At birth, anemia occurred in 13/140 infants (9%), neutropenia in 27/107 (25%), thrombocytopenia in 5/133 (4%), and liver enzyme elevation in 21/130 (16%).
Corresponding rates of AE at 4 weeks were 59/141 (42%), 54/130 (42%), 3/137 (2%), and 3/104 (3%), respectively.
Serious AE (grade ≥ 3) exceeded 2% only for neutropenia (13% at birth; 9% at 4 weeks).
Compared with infants exposed to maternal lopinavir/ritonavir, infants exposed to nelfinavir and atazanavir had a 5-fold and 4-fold higher incidence of AE at birth, respectively.
In conclusion, hematologic and hepatic AE were frequent, but rarely serious.
In this predominantly protease inhibitor-treated population, lopinavir/ritonavir was associated with the lowest rate of infant AE.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Smith, Christiana& Weinberg, Adriana& Forster, Jeri E.& Levin, Myron J.& Davies, Jill& Pappas, Jennifer…[et al.]. 2016. Maternal LopinavirRitonavir Is Associated with Fewer Adverse Events in Infants than Nelfinavir or Atazanavir. Infectious Diseases in Obstetrics and Gynecology،Vol. 2016, no. 2016, pp.1-9.
https://search.emarefa.net/detail/BIM-1104881
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Smith, Christiana…[et al.]. Maternal LopinavirRitonavir Is Associated with Fewer Adverse Events in Infants than Nelfinavir or Atazanavir. Infectious Diseases in Obstetrics and Gynecology No. 2016 (2016), pp.1-9.
https://search.emarefa.net/detail/BIM-1104881
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Smith, Christiana& Weinberg, Adriana& Forster, Jeri E.& Levin, Myron J.& Davies, Jill& Pappas, Jennifer…[et al.]. Maternal LopinavirRitonavir Is Associated with Fewer Adverse Events in Infants than Nelfinavir or Atazanavir. Infectious Diseases in Obstetrics and Gynecology. 2016. Vol. 2016, no. 2016, pp.1-9.
https://search.emarefa.net/detail/BIM-1104881
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1104881
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
![](/images/ebook-kashef.png)
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر
![](/images/kashef-image.png)